Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2022 Sep 27

PMID 36164553

Authors

Fenfen Gu

Chuling Hu

Wei Cao

Chao Li

Qingming Xia

Yuan Gao

Yan Liu

Shen Gao

Affiliations

Soon will be listed here.

Abstract

Introduction: Currently, the main treatment for advanced breast cancer is still chemotherapy. Immunological and chemical combination therapy has a coordinated therapeutic effect and achieves some efficacy. However, the immunosuppressive tumor microenvironment is a major cause for the failure of immunotherapy in breast cancer. CpG oligodeoxynucleotides can activate the tumor immune microenvironment to reverse the failure of immunotherapy.

Methods: In this study, we designed an amphiphilic peptide micelle system (Co-LMs), which can targeted delivery of the immune adjuvant CpG and the chemotherapeutic drug doxorubicin to breast cancer tumors simultaneously. The peptide micelle system achieved tumor microenvironment pH and redox-sensitive drug release.

Results And Discussion: Co-LMs showed 2.3 times the antitumor efficacy of chemotherapy alone and 5.1 times the antitumor efficacy of immunotherapy alone in triple-negative breast cancer mice. Co-LMs activated cytotoxic CD8+ T lymphocytes and CD4+ T cells in mice to a greater extent than single treatments. We also found that Co-LMs inhibited the metastasis of circulating tumor cells in the bloodstream to some extent. These results indicate that the Co-LMs offer a promising therapeutic strategy against triple-negative breast cancer.

Citing Articles

Orchestrating cancer therapy: Recent advances in nanoplatforms harmonize immunotherapy with multifaceted treatments.

Xu R, Lin P, Zheng J, Lin Y, Mai Z, Lu Y Mater Today Bio. 2025; 30:101386.

PMID: 39742149 PMC: 11683241. DOI: 10.1016/j.mtbio.2024.101386.

Plasmacytoid Dendritic Cells Mediate CpG-ODN-induced Increase in Survival in a Mouse Model of Lymphangioleiomyomatosis.

Amosu M, Jankowski A, McCright J, Yang B, Grano de Oro Fernandez J, Moore K Am J Respir Cell Mol Biol. 2024; 71(5):519-533.

PMID: 38990702 PMC: 11568470. DOI: 10.1165/rcmb.2023-0410OC.

Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer.

Wang R, Huang X, Chen X, Zhang Y ACS Biomater Sci Eng. 2024; 10(6):3568-3598.

PMID: 38815129 PMC: 11167598. DOI: 10.1021/acsbiomaterials.4c00108.

Stimuli-sensitive biomimetic nanoparticles for the inhibition of breast cancer recurrence and pulmonary metastasis.

Yang D, Zhang L, Ni J, Ding Y, Razzaq A, Khan Z Int J Pharm X. 2024; 7:100252.

PMID: 38766479 PMC: 11101870. DOI: 10.1016/j.ijpx.2024.100252.

Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies.

Chaudhari R, Patel V, Kumar A Nanoscale Adv. 2024; 6(9):2270-2286.

PMID: 38694472 PMC: 11059480. DOI: 10.1039/d4na00086b.

References

Mastria E, Cai L, Kan M, Li X, Schaal J, Fiering S . Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity. J Control Release. 2017; 269:364-373. PMC: 6475912. DOI: 10.1016/j.jconrel.2017.11.021. View

Midoux P, Pichon C, Yaouanc J, Jaffres P . Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol. 2009; 157(2):166-78. PMC: 2697805. DOI: 10.1111/j.1476-5381.2009.00288.x. View

Yin J, Ren W, Yang G, Duan J, Huang X, Fang R . L-Cysteine metabolism and its nutritional implications. Mol Nutr Food Res. 2015; 60(1):134-46. DOI: 10.1002/mnfr.201500031. View

Lachelt U, Kos P, Mickler F, Herrmann A, Salcher E, Rodl W . Fine-tuning of proton sponges by precise diaminoethanes and histidines in pDNA polyplexes. Nanomedicine. 2013; 10(1):35-44. DOI: 10.1016/j.nano.2013.07.008. View

Song Q, Yin Y, Shang L, Wu T, Zhang D, Kong M . Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy. Nano Lett. 2017; 17(10):6366-6375. DOI: 10.1021/acs.nanolett.7b03186. View

Zhu G, Lynn G, Jacobson O, Chen K, Liu Y, Zhang H . Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat Commun. 2017; 8(1):1954. PMC: 5715147. DOI: 10.1038/s41467-017-02191-y. View

Wang C, Sun W, Wright G, Wang A, Gu Z . Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody. Adv Mater. 2016; 28(40):8912-8920. PMC: 5283805. DOI: 10.1002/adma.201506312. View

Chan K, Tay J . Advancement of Peptide Nanobiotechnology via Emerging Microfluidic Technology. Micromachines (Basel). 2019; 10(10). PMC: 6843689. DOI: 10.3390/mi10100627. View

Labani-Motlagh A, Ashja-Mahdavi M, Loskog A . The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Front Immunol. 2020; 11:940. PMC: 7243284. DOI: 10.3389/fimmu.2020.00940. View

10.

Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, Sporchia A . Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. Clin Breast Cancer. 2015; 15(4):259-65. DOI: 10.1016/j.clbc.2015.03.002. View

11.

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

12.

Gong C, Hu C, Gu F, Xia Q, Yao C, Zhang L . Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment. J Control Release. 2017; 266:272-286. DOI: 10.1016/j.jconrel.2017.09.042. View

13.

Noguchi E, Shien T, Iwata H . Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. Jpn J Clin Oncol. 2020; 51(3):321-332. DOI: 10.1093/jjco/hyaa230. View

14.

Hu C, Gu F, Gong C, Xia Q, Gao Y, Gao S . Co-delivery of the autophagy inhibitor si-Beclin1 and the doxorubicin nano-delivery system for advanced prostate cancer treatment. J Biomater Appl. 2021; 36(7):1317-1331. DOI: 10.1177/08853282211060252. View

15.

Fan W, Yung B, Huang P, Chen X . Nanotechnology for Multimodal Synergistic Cancer Therapy. Chem Rev. 2017; 117(22):13566-13638. DOI: 10.1021/acs.chemrev.7b00258. View

16.

Futaki S . Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev. 2005; 57(4):547-58. DOI: 10.1016/j.addr.2004.10.009. View

17.

Retecki K, Seweryn M, Graczyk-Jarzynka A, Bajor M . The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. Cancers (Basel). 2021; 13(23). PMC: 8657247. DOI: 10.3390/cancers13236012. View

18.

Chan K, Lee W, Ni M, Loo Y, Hauser C . C-Terminal Residue of Ultrashort Peptides Impacts on Molecular Self-Assembly, Hydrogelation, and Interaction with Small-Molecule Drugs. Sci Rep. 2018; 8(1):17127. PMC: 6244206. DOI: 10.1038/s41598-018-35431-2. View

19.

Melero I, Berman D, Aznar M, Korman A, Perez Gracia J, Haanen J . Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015; 15(8):457-72. DOI: 10.1038/nrc3973. View

20.

Yao C, Liu J, Wu X, Tai Z, Gao Y, Zhu Q . Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy. J Control Release. 2016; 232:203-14. DOI: 10.1016/j.jconrel.2016.04.034. View